JP2023546140A - パーキンソン病の治療のためのオピカポン及びレボドパ - Google Patents

パーキンソン病の治療のためのオピカポン及びレボドパ Download PDF

Info

Publication number
JP2023546140A
JP2023546140A JP2023523099A JP2023523099A JP2023546140A JP 2023546140 A JP2023546140 A JP 2023546140A JP 2023523099 A JP2023523099 A JP 2023523099A JP 2023523099 A JP2023523099 A JP 2023523099A JP 2023546140 A JP2023546140 A JP 2023546140A
Authority
JP
Japan
Prior art keywords
levodopa
opicapone
combination
pharmaceutically acceptable
acceptable derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023523099A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022081033A5 (https=
JP2023546140A5 (https=
Inventor
パトリシオ、マヌエル、ビエイラ、アラウホ、ソアレス、ダ、シルバ
ホセ、フランシスコ、ダ、コスタ、デ、ピノ、ロチャ
Original Assignee
ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ filed Critical ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ
Publication of JP2023546140A publication Critical patent/JP2023546140A/ja
Publication of JPWO2022081033A5 publication Critical patent/JPWO2022081033A5/ja
Publication of JP2023546140A5 publication Critical patent/JP2023546140A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023523099A 2020-10-16 2021-10-14 パーキンソン病の治療のためのオピカポン及びレボドパ Pending JP2023546140A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2016425.7A GB202016425D0 (en) 2020-10-16 2020-10-16 Treatment regimens for parkinson's disease
GB2016425.7 2020-10-16
PCT/PT2021/050036 WO2022081033A1 (en) 2020-10-16 2021-10-14 Opicapone and levodopa for the treatment of parkinson's disease

Publications (3)

Publication Number Publication Date
JP2023546140A true JP2023546140A (ja) 2023-11-01
JPWO2022081033A5 JPWO2022081033A5 (https=) 2024-10-11
JP2023546140A5 JP2023546140A5 (https=) 2024-10-11

Family

ID=73598546

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023523099A Pending JP2023546140A (ja) 2020-10-16 2021-10-14 パーキンソン病の治療のためのオピカポン及びレボドパ

Country Status (8)

Country Link
US (1) US20230398105A1 (https=)
EP (1) EP4228618A1 (https=)
JP (1) JP2023546140A (https=)
KR (1) KR20230088753A (https=)
CN (1) CN116490171A (https=)
AU (1) AU2021360114A1 (https=)
GB (1) GB202016425D0 (https=)
WO (1) WO2022081033A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3860603A1 (en) 2018-10-05 2021-08-11 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
JP2024500754A (ja) * 2020-12-17 2024-01-10 ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ 早期特発性パーキンソン病のための治療レジメン
GB202212082D0 (en) * 2022-08-18 2022-10-05 Bial Portela & Ca Sa Treatment regimens for parkinson's disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020023540A (ja) * 2019-10-11 2020-02-13 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110002462A (ko) 2008-03-17 2011-01-07 바이알 - 포르텔라 앤드 씨에이 에스에이 5-[3-(2,5-디클로로-4,6-디메틸-1-옥시-피리딘-3-일)-[1,2,4]옥사디아졸-5-일]-3-나이트로벤젠-1,2-디올의 결정형
AU2010231961B2 (en) 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
RU2550133C2 (ru) 2009-04-01 2015-05-10 БИАЛ-ПОРТЕЛА энд КА., С.А. Фармацевтические составы, включающие производные нитрокатехола, и способы их получения
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
WO2013089573A1 (en) 2011-12-13 2013-06-20 BIAL - PORTELA & Cª., S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
JP2018500300A (ja) * 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
RU2018110580A (ru) * 2015-08-27 2019-09-30 Прекстон Терапьютикс Са Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии
MX383906B (es) * 2015-10-09 2025-03-14 Teva Pharmaceuticals Int Gmbh Combinación de levodopa deuterado con carbidopa y opicapona para el tratamiento del mal de parkinson

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020023540A (ja) * 2019-10-11 2020-02-13 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF NEUROLOGY, vol. 26, JPN6025050240, 2019, pages 953 - 960, ISSN: 0005747393 *
JAMA NEUROLOGY, vol. 74, JPN6025050238, 2017, pages 197 - 206, ISSN: 0005747394 *
MOVEMENT DISORDERS, vol. 35, JPN6025050241, September 2020 (2020-09-01), pages 1, ISSN: 0005747392 *

Also Published As

Publication number Publication date
GB202016425D0 (en) 2020-12-02
AU2021360114A9 (en) 2024-10-17
EP4228618A1 (en) 2023-08-23
AU2021360114A1 (en) 2023-06-08
WO2022081033A1 (en) 2022-04-21
KR20230088753A (ko) 2023-06-20
US20230398105A1 (en) 2023-12-14
CN116490171A (zh) 2023-07-25

Similar Documents

Publication Publication Date Title
US20250275934A1 (en) Medicaments for slowing parkinson's disease
JP2023546140A (ja) パーキンソン病の治療のためのオピカポン及びレボドパ
JP6951976B2 (ja) 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現
JP2024500754A (ja) 早期特発性パーキンソン病のための治療レジメン
JP2009500420A (ja) エスゾピクロン及びｏ−デスメチルベンラファキシンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
KR20180034442A (ko) 아캄프로세이트와 d-사이클로세린을 사용한 병용 치료
Otto et al. The Use of Intravenous Glutathione for Symptom Management of Parkinson's Disease: A Case Report.
JP2024527175A (ja) レボドパと組み合わせるオピカポンを用いたパーキンソン病に関連する疼痛の治療
US20260053782A1 (en) Treatment regimens for parkinson's disease
CA3076180C (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
Musey et al. Medical therapies for motor symptoms in Parkinson’s Disease
Borgohain et al. Efficacy and safety of safinamide in patients with Parkinson's disease experiencing motor fluctuations: results of a 6-month Phase III, randomized, double-blind, placebo-controlled study
EP2891491A1 (en) Use of (r)-phenylpiracetam for the treatment of sleep disorders
WO2025188619A1 (en) Methods of treating parkinson's disease with t-type calcium channel modulators
JPWO2020189781A1 (ja) パーキンソン病治療剤
Fahn Treatment of Parkinson’s Disease
Reichmann et al. NEW DEVELOPMENTS FOR PARKINSON’S THERAPY WITH COMT INHIBITORS
Valadas et al. Medical Treatment of Parkinson’s Disease
Salín-Pascual et al. Effects of venlafaxine in sleep of narcoleptic patients
HK40027687A (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
HK1119078A (en) Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
Katzenschlager of Parkinson’s Disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241002

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260225